<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Genetic evaluation of cardiomyopathy: HFSA 2010 comprehensive heart failure practice guideline.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Genetic evaluation of cardiomyopathy: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e180-94. [109 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); General physical examination  (89.7); Heart failure, unspecified  (428.9); Hypertrophic obstructive cardiomyopathy  (425.11); Other specified congenital anomalies of heart  (746.89); Unspecified congenital anomaly of heart  (746.9)"/><FieldValue Value="MSH: Arrhythmogenic Right Ventricular Dysplasia ; Cardiomyopathies ; Cardiomyopathy, Dilated ; Cardiomyopathy, Hypertrophic ; Cardiomyopathy, Restrictive ; Echocardiography ; Electrocardiography ; Electrocardiography, Ambulatory ; Exercise Test ; Fabry Disease ; Genetic Counseling ; Genetic Testing ; Heart Defects, Congenital ; Heart Failure ; Individualized Medicine ; Isolated Noncompaction of the Ventricular Myocardium ; Magnetic Resonance Imaging ; Medical History Taking ; Physical Examination ; Referral and Consultation "/><FieldValue Value="MTH: Cardiomyopathies ; Cardiomyopathy, Dilated ; Congenital Heart Defects ; Creatine Kinase MM Measurement ; Echocardiography ; Electrocardiography ; Electrocardiography, Ambulatory ; Exercise stress test ; Fabry Disease ; Family counseling ; Genetic Counseling ; Genetic screening method ; Heart failure ; Holter Monitors ; Hypertrophic Cardiomyopathy ; Magnetic Resonance Imaging ; Phenotype determination ; physical examination ; Restrictive cardiomyopathy "/><FieldValue Value="PDQ: magnetic resonance imaging "/><FieldValue Value="SNOMEDCT_US: Ambulatory ECG  (164850009); Arrhythmogenic right ventricular dysplasia  (253528005); Arrhythmogenic right ventricular dysplasia  (281170005); Cardiomyopathy  (57809008); Cardiomyopathy  (85898001); Dilated cardiomyopathy  (195021004); Dilated cardiomyopathy  (399020009); Echocardiography  (40701008); Electrocardiographic monitor and recorder  (86184003); Electrocardiographic procedure  (29303009); Exercise tolerance test  (165079009); f - Family history  (277652007); Fabry's disease  (124464003); Fabry's disease  (16652001); Family counseling  (311764000); Family history of congenital anomaly of cardiovascular system  (266908007); Genetic counseling  (79841006); Genetic test  (405824009); Heart failure  (84114007); Hypertrophic cardiomyopathy  (233873004); Hypertrophic cardiomyopathy  (45227007); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Phenotype determination  (363778006); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Restrictive cardiomyopathy  (415295002); Restrictive cardiomyopathy  (90828009)"/><FieldValue Value="SPN: SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING "/><FieldValue Value="UMD: Data Processors, Electronic Recording, Electrocardiography  (24-525); Physiologic Monitor Modules, Electrocardiography  (20-771); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Ultrasonic, Cardiac  (17-422)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Cardiomyopathy &lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: These guidelines use the generic term 'cardiomyopathy' to imply possible familial or genetic cause, assuming that all other detectable causes of cardiomyopathy have been ruled out.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Medical Genetics" /><FieldValue Value="Pediatrics" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide recommendations for the genetic evaluation of cardiomyopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To update and expand the previous 2006 clinical practice guidelines &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients and their blood relatives with, or at risk for, cardiomyopathy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation/Diagnosis/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Family history for &amp;ge;3 generations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical screening including:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;History &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Electrocardiogram (ECG) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Echocardiogram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Creatine kinase MM isoenzyme (CK-MM) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Signal averaged ECG (SAECG) in arrhythmic right ventricular dysplasia (ARVD) only &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Holter monitoring in hypertrophic cardiomyopathy (HCM), ARVD &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise treadmill testing in HCM &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Magnetic resonance imaging in ARVD &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Referral to genetic expert centers should be considered &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Molecular genetic testing including cardiomyopathy phenotype, specific genes, and Fabry disease, when applicable &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic and family counseling &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medical therapy based on cardiac phenotype &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening yield for cardiomyopathy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A literature search with relevant key words and phrases for each guideline section were provided to members of the subcommittees and the full Guideline Committee. Members of each subcommittee were asked to review the search and identify any additional relevant medical evidence for each assigned section.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following databases were searched:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ovid Medline (1950 to the updated date when the search was conducted) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ovid Medline In-Process and other Non-Indexed Citations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PubMed &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The searches focused primarily on the period between the last guideline publication and current, although the authors went back to 2005 to account for publication lag between the completion of the guideline and its publication in 2006 (i.e., 2005&amp;ndash;2010) in the event there was some information that should/could be added to the 2010 updated document. Generally only non-human studies and publications that were non-English were excluded.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Hierarchy of Types of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength A&lt;/strong&gt; The specific genetic test or clinical test has a high correlation with the cardiomyopathic disease of interest in reasonably large studies from multiple centers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength B&lt;/strong&gt; The specific genetic test or clinical test has a high correlation with the cardiomyopathic disease of interest in small or single center studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength C&lt;/strong&gt; The specific genetic test or clinical test correlates with the cardiomyopathic disease of interest in case reports.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Heart Failure Society of America (HFSA)&amp;nbsp;Guideline Approach to Medical Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Two considerations are critical in the development of practice guidelines: assessing strength of evidence and determining strength of recommendation. Strength of evidence is determined both by the type of evidence available and the assessment of validity, applicability, and certainty of a specific type of evidence. Following the lead of previous guidelines, strength of evidence in this guideline is heavily dependent on the source or type of evidence used. The HFSA guideline process has used three grades (A, B, or C) to characterize the type of evidence available to support specific recommendations (see Table 1.2 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;HFSA Guideline Approach to Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Determining Strength. Although level of evidence is important, the strength given to specific recommendations is critical. The process used to determine the strength of individual recommendations is complex. The goal of guideline development is to achieve the best recommendations for evaluation and management, considering not only efficacy, but the cost, convenience, side effect profile, and safety of various therapeutic approaches. The HFSA guideline committee often determined the strength of a recommendation by the &quot;totality of evidence,&quot; which is a synthesis of all types of available data, pro and con, about a particular therapeutic option. The HFSA guideline employs the categorization for strength of recommendation outlined in Table 1.3 in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Process of Guideline Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Key steps in the development of this guideline are listed in Table 1.4 in the original guideline document. Having determined the broad scope of the current guideline, subcommittees of the guideline committee were formed for each section of the guideline. A literature search with relevant key words and phrases for each guideline section were provided to members of the subcommittees and the full Guideline Committee. Members of each subcommittee were asked to review the search and identify any additional relevant medical evidence for each assigned section. Changes in recommendation and background were carried out by each subcommittee with conference calls directed by the Guideline Committee chair. Each section was presented for comments and consensus approval to the Guideline Committee. Once subsections were complete, the Executive Council reviewed and commented on each section and these comments were returned to the Guideline Committee for changes and once complete, for final approval by the Executive Council.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Heart Failure Society of America (HFSA) Guideline Committee sought resolution of difficult cases through consensus building. An open, dynamic discussion meant that no single voice was allowed to dominate. Written documents were essential to this process, because they provided the opportunity for feedback from all members of the group. On occasion, consensus of opinion was sufficient to override positive or negative results of almost any form of evidence. The HFSA process had a strong commitment to recommendations based on objective evidence rigorously reviewed by a panel of experts. Issues that caused difficulty for the HFSA guideline process were some of the more important ones faced by the committee, because they mirrored those that are often most challenging to clinicians in day-to-day practice. The foundation of the HFSA guideline process was the belief that the careful judgment of recognized opinion leaders in these controversial areas is more likely to be correct than ad hoc decisions made &quot;on the spot&quot; by physicians in practice.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classifying the Strength of the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Classifying the Strength of the Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Part of routine care&lt;br /&gt;&#xD;&#xA;            Exceptions to therapy should be minimized. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Should be considered&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Majority of patients should receive the intervention.&lt;br /&gt;&#xD;&#xA;            Some discretion in application to individual patients should be allowed.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;May be considered&quot; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Individualization of therapy is indicated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is not recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Therapeutic intervention should not be used&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Each section was presented for comments and consensus approval to the Guideline Committee. Once subsections were complete, the Executive Council reviewed and commented on each section and these comments were returned to the Guideline Committee for changes and once complete, for final approval by the Executive Council.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The strength of evidence (A, B, C) and strength of recommendations are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Note from Heart Failure Society of America (HFSA)&lt;/strong&gt;&lt;/em&gt;: This section organizes recommendations by cardiac phenotype, recognizing that there is substantial overlap among phenotypes and some mutations are associated with more than one phenotype. Because therapeutic decision-making is generally dictated by phenotype, this approach was considered most helpful for the clinician.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;HFSA Guideline Approach to Medical Evidence for Genetic Evaluation of Cardiomyopathy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A careful family history for &amp;ge;3 generations is recommended for all patients with cardiomyopathy.&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: HFSA Guideline Approach to Medical Evidence for Genetic Evaluation of Cardiomyopathy&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;p&gt;Hypertrophic cardiomyopathy (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Dilated cardiomyopathy (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Arrhythmogenic right ventricular dysplasia (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Left ventricular noncompaction (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Restrictive cardiomyopathy (Strength of Evidence = B)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Cardiomyopathies associated with extracardiac manifestations (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinical screening for cardiomyopathy in asymptomatic first-degree relatives is recommended.&#xD;&#xA;    &lt;p&gt;a.&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: HFSA Guideline Approach to Medical Evidence for Genetic Evaluation of Cardiomyopathy&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;p&gt;Hypertrophic cardiomyopathy (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Dilated cardiomyopathy (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Arrhythmogenic right ventricular dysplasia (Strength of Evidence = A) &lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Left ventricular noncompaction (Strength of Evidence = B)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Restrictive cardiomyopathy (Strength of Evidence = B)&lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Cardiomyopathies associated with extracardiac manifestations (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;b.&amp;nbsp;Clinical screening for cardiomyopathy is recommended at intervals (see Table below) in asymptomatic at-risk relatives who are known to carry the disease-causing mutation(s). (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;c.&amp;nbsp;Clinical screening for cardiomyopathy is recommended for asymptomatic at-risk first-degree relatives when genetic testing has not been performed or has not identified a disease-causing mutation. (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;d.&amp;nbsp; It is recommended that clinical screening consist of:&lt;/p&gt;&#xD;&#xA;    &lt;blockquote&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;History (with special attention to heart failure symptoms, arrhythmias, presyncope and syncope) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical examination (with special attention to the cardiac and skeletal muscle systems) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Electrocardiogram (ECG) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Echocardiogram &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Creatine kinase (CK-MM) (at initial evaluation only) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Signal Averaged electrocardiogram (SAECG) in arrhythmogenic right ventricular dysplasia (ARVD) only &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Holter monitoring in hypertrophic cardiomyopathy (HCM), ARVD &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise treadmill testing in HCM &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Magnetic resonance imaging in ARVD (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/blockquote&gt;&#xD;&#xA;    &lt;p&gt;e.&amp;nbsp;Clinical screening for cardiomyopathy should be considered at the following times and intervals or at any time that signs or symptoms appear (see Table below)&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Table: Clinical Screening for Cardiomyopathy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Clinical Screening for Cardiomyopathy&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;thead&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Cardiomyopathy Phenotype&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Interval if Genetic Testing Is Negative and/or if Clinical Family Screening Is Negative&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Screening Interval if a Mutation Is Present&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Strength of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/thead&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Hypertrophic&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3 years until 30 years of age, except yearly during puberty; after 30 years if symptoms develop&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3 years until 30 years of age, except yearly during puberty; every 5 years thereafter&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Dilated&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3-5 years beginning in childhood&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Yearly in childhood; every 1-3 years in adults.&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;ARVD&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3-5 years after age 10&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Yearly after age 10 to 50 years of age.&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;LVNC&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3 years beginning in childhood&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Yearly in childhood; every 1-3 years in adults.&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Restrictive&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3-5 years beginning in adulthood&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Yearly in childhood; every 1-3 years in adults.&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;f.&amp;nbsp; At-risk first-degree relatives with any abnormal clinical screening tests (regardless of genotype) should be considered for repeat clinical screening at one year. (Strength of Evidence = C)&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evaluation, genetic counseling, and genetic testing of cardiomyopathy patients are complex processes. Referral to centers expert in genetic evaluation and family-based management should be considered. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Molecular Genetic Testing &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;Genetic testing should be considered for the one most clearly affected person in a family to facilitate family screening and management.&#xD;&#xA;    &lt;p&gt;a.&amp;nbsp;Cardiomyopathy phenotype&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Cardiomyopathy phenotype&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;p&gt;Hypertrophic cardiomyopathy (Strength of Evidence = A) &lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Dilated cardiomyopathy (Strength of Evidence = B) &lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Arrhythmogenic right ventricular dysplasia (Strength of Evidence = A) &lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Left ventricular noncompaction (Strength of Evidence = C) &lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Restrictive cardiomyopathy (Strength of Evidence = C) &lt;/p&gt;&#xD;&#xA;                &lt;p&gt;Cardiomyopathies associated with extracardiac manifestations (Strength of Evidence = A)&lt;/p&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;b.&amp;nbsp;Specific genes available for screening based on cardiac phenotype&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Table 5&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Specific genes available for screening based on cardiac phenotype&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;        &lt;thead&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Cardiomyopathy Phenotype&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Gene Tests Available*&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Yield of Positive Results&lt;/th&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/thead&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;HCM&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;MYH7, MYBPC3, TNNT2 TNNI3, TPMI, ACTC, MYL2, MYL3&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;MYH7, MYBPC3 each account for 30-40% of mutations, TNNT2 for 10-20%. Genetic cause can be identified in 35-45% overall; up to 60-65% when the family history is positive.&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;DCM&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;LMNA, MYH7, TNNT2, SCN5A, DES, MYBPC3, TNNI3, TPMI, ACTC, PLN, LDB3 and TAZ&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;5.5%, 4.2%, 2.9%, for LMNA, MYH7, and TNNT2, respectively. All data are from research cohorts.&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;ARVD&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;DSP, PKP2, DSG2, DSC2&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;6-16%, 11-43%, 12-40%, for DSP, PKP2 and DSG2, respectively&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;LVNC&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Uncertain &amp;ndash; see discussion in original guideline document&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Uncertain &amp;ndash; see discussion in original guideline document&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;RCM&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Uncertain &amp;ndash; see discussion in original guideline document&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Uncertain &amp;ndash; see discussion in original guideline document&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p class=&quot;Note&quot;&gt;* GeneTests (&lt;a href=&quot;http://www.genetests.org&quot; title=&quot;Genetests Web site&quot;&gt;www.genetests.org&lt;/a&gt;) is a National Institutes of Health (NIH) funded resource that lists clinical (and research) molecular genetic testing laboratories for the cardiomyopathies.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;c.&amp;nbsp;Screening for Fabry disease is recommended in all men with sporadic or non-autosomal dominant (no male-to-male) transmission of unexplained cardiac hypertrophy. (Strength of Evidence = B)&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Genetic Counseling&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;Genetic and family counseling is recommended for all patients and families with cardiomyopathy. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Therapy Based on Cardiac Phenotype&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;Medical therapy based on cardiac phenotype is recommended as outlined in the general guidelines. (Strength of Evidence = A) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Device therapies for arrhythmia and conduction system disease based on cardiac phenotype are recommended as outlined in the general guidelines. (Strength of Evidence = B) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In patients with cardiomyopathy and significant arrhythmia or known risk of arrhythmia an implantable cardioverter defibrillator (ICD) may be considered before the left ventricular ejection fraction falls below 35%. (Strength of Evidence = C) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Hierarchy of Types of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength A&lt;/strong&gt; The specific genetic test or clinical test has a high correlation with the cardiomyopathic disease of interest in reasonably large studies from multiple centers.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength B&lt;/strong&gt; The specific genetic test or clinical test has a high correlation with the cardiomyopathic disease of interest in small or single center studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength C&lt;/strong&gt; The specific genetic test or clinical test correlates with the cardiomyopathic disease of interest in case reports.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Classifying the Strength of the Recommendations&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Part of routine care&lt;br /&gt;&#xD;&#xA;            Exceptions to therapy should be minimized. &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Should be considered&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Majority of patients should receive the intervention.&lt;br /&gt;&#xD;&#xA;            Some discretion in application to individual patients should be allowed.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;May be considered&quot; &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Individualization of therapy is indicated.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&quot;Is not recommended&quot;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Therapeutic intervention should not be used&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cardiomyopathy can be treated in almost all cases, improving survival and/or enhancing quality of life. Further, determining genetic risk of cardiomyopathy prior to disease presentation guides the recommendations for increased surveillance to detect early disease onset and medical intervention. All of these measures may delay disease presentation and progression, thereby avoiding advanced therapies such as cardiac transplantation, or averting the sequelae of life-threatening events, such as sudden cardiac death. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Genetic counseling helps individuals understand the genetic information presented and use it to make informed decisions regarding genetic testing or other therapeutic decisions and to adapt to the medical, psychological and familial implications of genetic contributions to disease. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;It must be recognized that the evidence supporting recommendations is based largely on population responses that may not always apply to individuals within the population. Therefore, data may support overall benefit of one treatment over another but cannot exclude that some individuals within the population may respond better to the other treatment. Thus, guidelines can best serve as evidence-based recommendations for management, not as mandates for management in every patient. Furthermore, it must be recognized that trial data on which recommendations are based have often been carried out with background therapy not comparable to therapy in current use. Therefore, physician decisions regarding the management of individual patients may not always precisely match the recommendations. A knowledgeable physician who integrates the guidelines with pharmacologic and physiologic insight and knowledge of the individual being treated should provide the best patient management.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The value of a practice guideline is significantly influenced by the scope of its dissemination. The first and second Heart Failure Society of America guidelines were available on the Internet, and thousands of copies were downloaded. The current document will be implemented on the Internet both for file transfer and as a hypertext source of detailed knowledge concerning heart failure (HF).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Slide Presentation" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teerlink JR, Walsh MN. Genetic evaluation of cardiomyopathy: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun;16(6):e180-94. [109 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is adapted from the following source:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Reprinted with edits and permission from Hershberger RE, Lindenfeld J, Mestroni L, Seidman C, Taylor MRG, Towbin JA. Genetic evaluation of cardiomyopathy: A Heart Failure Society of America practice guideline. J Card Fail 2009;15:83-97. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Jun" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Heart Failure Society of America, Inc - Disease Specific Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Failure Society of America, Inc&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart Failure Society of America Guideline Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Guideline Committee Members&lt;/em&gt;: JoAnn Lindenfeld, MD (&lt;em&gt;Chair&lt;/em&gt;); Nancy M. Albert, RN, PhD; John P. Boehmer, MD; Sean P. Collins, MD, MSc; Justin A. Ezekowitz, MBBCh; Michael M. Givertz, MD; Stuart D. Katz, MD; Marc Klapholz, MD; Debra K. Moser, RN, DNSc; Joseph G. Rogers, MD; Randall C. Starling, MD, MPH; William G. Stevenson, MD; W.H. Wilson Tang, MD; John R. Teerlink, MD; Mary N. Walsh, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Executive Council&lt;/em&gt;: Douglas L. Mann, MD, President; Inder S. Anand, MD; J. Malcolm O. Arnold, MD; John C. Burnett, Jr., MD; John Chin, MD; Jay N. Cohn, MD; Thomas Force, MD; Barry H. Greenberg, MD; Steven R. Houser, PhD; Mariell L. Jessup, MD; Barry M. Massie, MD; Mandeep R. Mehra, MD; Mariann R. Piano, RN, PhD; Clyde W. Yancy, MD; Michael R. Zile, MD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Committee members and reviewers from the Executive Council received no direct financial support from the Heart Failure Society of America (HFSA) or any other source for the development of the guideline. Support was provided by the HFSA administrative staff, but the writing of the document was performed on a volunteer basis primarily by the Committee. Financial relationships that might represent conflicts of interest were collected annually from all members of the Guideline Committee and the Executive Council. Current relationships are shown in Appendix C of the &quot;2010 HFSA Guideline Executive Summary&quot; companion document (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.heartfailureguideline.org/&quot; title=&quot;HFSA Web site&quot;&gt;Heart Failure Society of America, Inc. Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Heart Failure Society of America, Inc., Court International - Suite 240 S, 2550 University Avenue West, Saint Paul, Minnesota 55114; Phone: (651) 642-1633&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Executive summary: The 2010 HFSA comprehensive heart failure practice guideline. J Card Fail 2010 Jun. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Development and implementation of a comprehensive heart failure practice guideline. J Card Fail 2010 Jun;16(6):e3-6. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart Failure Society of America. Conceptualization and working definition of heart failure. J Card Fail 2010 Jun;16(6):e34-7. Electronic copies: Available from the &lt;a href=&quot;http://www.onlinejcf.com/article/S1071-9164%2810%2900174-0/fulltext&quot; title=&quot;Journal of Cardiac Failure Web site&quot;&gt;Journal of Cardiac Failure Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;PowerPoint slides. HFSA 2010 comprehensive heart failure guideline. Electronic copies: Available from the &lt;a href=&quot;http://www.heartfailureguideline.org/slide_sets_all_recommendations/42&quot; title=&quot;HFSA Web site&quot;&gt;Heart Failure Society of America, Inc. Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the Heart Failure Society of America, Inc., Court International - Suite 240 South, 2550 University Avenue West, Saint Paul, Minnesota 55114; Phone: (651) 642-1633&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on October 21, 2010. The information was verified by the guideline developer on November 23, 2010.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please direct inquiries to &lt;a href=&quot;mailto:info@hfsa.org&quot;&gt;info@hfsa.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
